Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
Eligibility criteria
Qualifiers
Aged 18 years or older
AML diagnosis according to the ELN guidelines, excluding M3
Signed Informed consent, if applicable
patients affected by FLT3-mutated AML treated with gilteritinib.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov